Canostix aims to beat cancer, simply by diagnosing it so early, that it can be already cured today. We achieve this by developing a blood-based early detection test that combines photonics and machine learning. Starting with the five most common cancers, covering 50% of all cancer cases, we create a constantly evolving software solution that upgrades available hardware into top-of-the-line screening machines. This is done through a one-of-a-kind collaboration with leading Indian research institutes, which enables us to fast-track clinical translation. Our goal is to introduce an affordable cancer test at the primary care level that will result in less invasive treatments, ultimately saving billions of dollars and millions of lives. Currently, we are on hold due to the ongoing COVID19 lockdown in India and are waiting to start our population-scale clinical studies. In the meantime, we are using the time to make progress on the software infrastructure, regulatory strategy and preparing our next investment round.